Payment overview · 2025
General Payments
$510.26
20 reported records · 12 companies
Healthcare provider profile · identity verified
Philip Wayne Bibb, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WILMINGTON, NC · NPI 1598827180
Verified facts
What the public records show
CMS Open Payments records show Philip Wayne Bibb, PAC received $510.26 in general payments during 2025 across 20 reported records.
Ipsen Biopharmaceuticals, Inc accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $145.20 | 28.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.97 | 15.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.66 | 9.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.33 | 9.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.93 | 8.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.20 | 5.5% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.51 | 4.8% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $23.16 | 4.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.70 | 4.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.02 | 3.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.21 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $510.26 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $145.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.97 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $43.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| Persona Normalized: persona |
Device | Zimmer Biomet Holdings, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| mymobility Platform Normalized: mymobility platform |
Device | Zimmer Biomet Holdings, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 551 | 99 |
| Furosemide | Furosemide | 429 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 74 |
| Meloxicam | Meloxicam | 337 | 59 |
| Omeprazole | Omeprazole | 264 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 39 |
| Tramadol Hcl | Tramadol Hcl | 223 | 52 |
| Metformin Hcl | Metformin Hcl | 210 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 26 |
| Trazodone Hcl | Trazodone Hcl | 209 | 31 |
| Lisinopril | Lisinopril | 197 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 35 |
| Gabapentin | Gabapentin | 194 | 36 |
| Mirtazapine | Mirtazapine | 191 | 31 |
| Alprazolam | Alprazolam | 170 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 167 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 138 | 25 |
| Losartan Potassium | Losartan Potassium | 135 | 23 |
| Lorazepam | Lorazepam | 132 | 40 |
| Potassium Chloride | Potassium Chloride | 128 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 25 |
| Memantine Hcl | Memantine Hcl | 123 | 15 |
| Famotidine | Famotidine | 120 | 19 |
| Donepezil Hcl | Donepezil Hcl | 118 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 25 |
| Methylprednisolone | Methylprednisolone | 111 | 70 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 101 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 75 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 96 | 54 |
| Glipizide Er | Glipizide | 93 | 18 |
| Allopurinol | Allopurinol | 92 | 17 |
| Topiramate | Topiramate | 91 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | suppressed |
| Eliquis | Apixaban | 87 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 13 |
| Carvedilol | Carvedilol | 79 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 11 |
| Simvastatin | Simvastatin | 76 | 17 |
| Montelukast Sodium | Montelukast Sodium | 73 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | suppressed |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | suppressed |
| Pregabalin | Pregabalin | 58 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 14 |
| Ibuprofen | Ibuprofen | 48 | 18 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Baclofen | Baclofen | 47 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 11 |
| Atenolol | Atenolol | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 11 |
| Finasteride | Finasteride | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 34 |
| Valsartan | Valsartan | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Lacosamide | Lacosamide | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Tradjenta | Linagliptin | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 11 |
| Restasis | Cyclosporine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $510.26 · 20 records | Ipsen Biopharmaceuticals, Inc | CAPLYTA, FANAPT, HETLIOZ, IQIRVO, KISUNLA, Korlym, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PAXLOVID, Persona, REPATHA, REXULTI, UPTRAVI, Wegovy, mymobility Platform | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error